Quarterly report · Q2

Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥1.78T2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥3.36T2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥1.69T2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥20.6bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥25.5bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥29.3bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥65.1bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥33.3bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥32.8bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥33.3bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥17.2bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥38.8bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥17.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥22.5bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥21.9bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥1.82Tat 2023-09-30Cons.Assets
Total assets¥1.71Tat 2023-03-31Cons.Assets
Total assets¥1.74Tat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥1.10Tat 2023-09-30Cons.Liabilities
Total liabilities¥1.02Tat 2023-03-31Cons.Liabilities
Net assets / equity¥714.6bnat 2023-09-30Cons.Net assets
Net assets / equity¥688.1bnat 2023-03-31Cons.Net assets
Net assets / equity¥674.7bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥209.1bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥195.0bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥207.0bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥193.6bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥238.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥260.4bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥31.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥16.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥9.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥10.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥39.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥5.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥12.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥43.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥6.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥80.482023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥28.082023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥184.822022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥82.512022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥43.132022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥179.122022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥77.562022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio32.1%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio32.8%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio31.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥1.2bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥1.2bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥37m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥56.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥56.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.5bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥583.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥583.3bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥146m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥1.14T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.14T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1.1bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥5.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥1.78T
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥1.78T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥20.7bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥2.0bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥2.0bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥191m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥36.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥36.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥1.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥554.9bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥554.7bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥174m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.0bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.10T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.09T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥1.69T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥1.69T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥2.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥25.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 508
ItemContextValueUnit
Decrease increase in notes and accounts receivable trade ope cfCurrentYTDDuration-48985000000JPY
Decrease increase in inventories ope cfPrior1YTDDuration-1161000000JPY
Decrease increase in inventories ope cfCurrentYTDDuration-5392000000JPY
Increase decrease in notes and accounts payable trade ope cfPrior1YTDDuration-2621000000JPY
Increase decrease in notes and accounts payable trade ope cfCurrentYTDDuration52485000000JPY
Other net ope cfPrior1YTDDuration-7819000000JPY
Other net ope cfCurrentYTDDuration-753000000JPY
Subtotal ope cfPrior1YTDDuration1884000000JPY
Subtotal ope cfCurrentYTDDuration38373000000JPY
Interest and dividends income received ope cf inv cfPrior1YTDDuration2643000000JPY
Interest and dividends income received ope cf inv cfCurrentYTDDuration3798000000JPY
Interest expenses paid ope cf fin cfPrior1YTDDuration-3000000JPY
Interest expenses paid ope cf fin cfCurrentYTDDuration-1000000JPY
Proceeds from compensation ope cfPrior1YTDDuration-JPY
Proceeds from compensation ope cfCurrentYTDDuration2768000000JPY
Payments for loss on disaster ope cfPrior1YTDDuration-584000000JPY
Payments for loss on disaster ope cfCurrentYTDDuration-JPY
Income taxes paid ope cfPrior1YTDDuration-13467000000JPY
Income taxes paid ope cfCurrentYTDDuration-13723000000JPY
Net cash provided by used in operating activitiesPrior1YTDDuration-9527000000JPY
Net cash provided by used in operating activitiesCurrentYTDDuration31215000000JPY
Purchase of property plant and equipment inv cfPrior1YTDDuration-7889000000JPY
Purchase of property plant and equipment inv cfCurrentYTDDuration-10730000000JPY
Proceeds from sales of property plant and equipment inv cfPrior1YTDDuration77000000JPY
Proceeds from sales of property plant and equipment inv cfCurrentYTDDuration3000000JPY
Purchase of investment securities inv cfPrior1YTDDuration-143000000JPY
Purchase of investment securities inv cfCurrentYTDDuration-136000000JPY
Proceeds from sales and redemption of investment securities inv cfPrior1YTDDuration4919000000JPY
Proceeds from sales and redemption of investment securities inv cfCurrentYTDDuration1192000000JPY
Other net inv cfPrior1YTDDuration-2679000000JPY
Other net inv cfCurrentYTDDuration-1129000000JPY
Net cash provided by used in investment activitiesPrior1YTDDuration-5715000000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration-10800000000JPY
Purchase of treasury stock fin cfPrior1YTDDuration-0JPY
Purchase of treasury stock fin cfCurrentYTDDuration-5983000000JPY
Cash dividends paid fin cfPrior1YTDDuration-4829000000JPY
Cash dividends paid fin cfCurrentYTDDuration-4829000000JPY
Dividends paid to non controlling interests fin cfPrior1YTDDuration-1208000000JPY
Dividends paid to non controlling interests fin cfCurrentYTDDuration-1270000000JPY
Other net fin cfPrior1YTDDuration-644000000JPY
Other net fin cfCurrentYTDDuration-654000000JPY
Net cash provided by used in financing activitiesPrior1YTDDuration-6683000000JPY
Net cash provided by used in financing activitiesCurrentYTDDuration-12738000000JPY
Effect of exchange rate change on cash and cash equivalentsPrior1YTDDuration0JPY
Effect of exchange rate change on cash and cash equivalentsCurrentYTDDuration0JPY
Net increase decrease in cash and cash equivalentsPrior1YTDDuration-21925000000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration7677000000JPY
Cash and cash equivalentsPrior2YearInstant260450000000JPY
Cash and cash equivalentsPrior1YearInstant193561000000JPY
Increase in cash and cash equivalents from newly consolidated subsidiary ccePrior1YTDDuration-JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass